Home Featured Page 140

Featured

Latest

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S-...

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle...

Interview | George Tziras, Small Pharma

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases...

1...139140141...303 Page 140 of 303

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and Competition

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic Work

Navigators Film Club – Last Journey

Alexander Beiner – Psychedelics, Culture, and the Games We Play

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial...

MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S-...

KetaMD Expands Access to Breakthrough Ketamine Therapy in Florida to Battle...

Interview | George Tziras, Small Pharma

Combating Suicidality: A Role for Psilocybin and Ayahuasca?

PT361 – Jason Slot, Ph.D. – Mycology and Evolutionary Genomics

Silo Pharma Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released...

Reunion Neuroscience to Participate in the Cantor Neurology & Psychiatry Conference

Silo Pharma Announces Closing of $5.75 Million Public Offering of Common...

Psychedelic Bulletin #119: More Misery for MindMed; Another Psychedelics Co. Ceases...

EDITOR PICKS

What the Cancer Community Actually Needs from Psychedelic Care

Bringing Psilocybin to Market: Compass’ Steve Levine on Infrastructure, Access and...

Joe Moore & Kyle Buller: Breathwork, Somatics, and Foundations for Psychedelic...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY